ACADIA Pharmaceuticals Inc.
$29.50
The Read: 9% when key Phase 3 data was delayed, and showed minimal reaction to earnings matching estimates without new catalysts.
ACAD
Hover to view data
No Data
By creating an account you agree to our Terms of Service and Privacy Policy.
$29.50
The Read: 9% when key Phase 3 data was delayed, and showed minimal reaction to earnings matching estimates without new catalysts.
No Data